CA3157315A1 - Cancer treatments targeting cancer stem cells - Google Patents
Cancer treatments targeting cancer stem cells Download PDFInfo
- Publication number
- CA3157315A1 CA3157315A1 CA3157315A CA3157315A CA3157315A1 CA 3157315 A1 CA3157315 A1 CA 3157315A1 CA 3157315 A CA3157315 A CA 3157315A CA 3157315 A CA3157315 A CA 3157315A CA 3157315 A1 CA3157315 A1 CA 3157315A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- substituted
- unsubstituted
- cancer
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962931531P | 2019-11-06 | 2019-11-06 | |
| US62/931,531 | 2019-11-06 | ||
| PCT/US2020/059329 WO2021092322A1 (en) | 2019-11-06 | 2020-11-06 | Cancer treatments targeting cancer stem cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3157315A1 true CA3157315A1 (en) | 2021-05-14 |
Family
ID=73643356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3157315A Pending CA3157315A1 (en) | 2019-11-06 | 2020-11-06 | Cancer treatments targeting cancer stem cells |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP4055008A1 (https=) |
| JP (2) | JP7690470B2 (https=) |
| KR (1) | KR20220110744A (https=) |
| CN (2) | CN119930509A (https=) |
| AU (1) | AU2020378067A1 (https=) |
| BR (1) | BR112022008753A2 (https=) |
| CA (1) | CA3157315A1 (https=) |
| CO (1) | CO2022007910A2 (https=) |
| IL (1) | IL292718A (https=) |
| MX (1) | MX2022005445A (https=) |
| PH (1) | PH12022551081A1 (https=) |
| WO (1) | WO2021092322A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102831570B1 (ko) | 2018-05-04 | 2025-07-10 | 레미디 플랜, 인크. | 암 줄기 세포를 표적화하는 암 치료 |
| JP2024518089A (ja) * | 2021-05-13 | 2024-04-24 | リメディー プラン，インコーポレーテッド | Ｎａｍｐｔ阻害剤とその使用 |
| WO2024049225A1 (ko) | 2022-09-01 | 2024-03-07 | 주식회사 엘지에너지솔루션 | 이차 전지 및 이를 포함하는 디바이스 |
| CN116139141A (zh) * | 2022-12-14 | 2023-05-23 | 复旦大学 | Agk2促进肝癌的免疫治疗的用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19624659A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| DE19624668A1 (de) | 1996-06-20 | 1998-02-19 | Klinge Co Chem Pharm Fab | Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden |
| WO2008016643A2 (en) * | 2006-08-01 | 2008-02-07 | Cytokinetics, Incorporated | Certain chemical entities, compositions, and methods |
| WO2008026018A1 (en) | 2006-09-01 | 2008-03-06 | Topotarget Switzerland Sa | New method for the treatment of inflammatory diseases |
| FR2921657A1 (fr) * | 2007-09-28 | 2009-04-03 | Sanofi Aventis Sa | Derives de nicotinamide, leur preparation et leur application en therapeutique |
| EP2098231A1 (en) | 2008-03-05 | 2009-09-09 | Topotarget Switzerland SA | Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury |
| CA2877474A1 (en) * | 2011-06-20 | 2012-12-27 | Myrexis, Inc. | Compounds and therapeutic uses thereof |
| HK1211832A1 (zh) | 2012-05-07 | 2016-10-14 | The General Hospital Corporation | 用於癌症療法的抗高血壓藥物的新穎配方及用法 |
| ES2774330T3 (es) | 2013-04-09 | 2020-07-20 | Massachusetts Inst Technology | Polímero de suministro de fármaco y usos del mismo |
| TW201625641A (zh) * | 2014-05-22 | 2016-07-16 | 健臻公司 | Ｎａｍｐｔ抑制劑及方法 |
| US11078195B2 (en) * | 2016-03-17 | 2021-08-03 | Checkmate Therapeutics Inc. | Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same |
| KR102831570B1 (ko) * | 2018-05-04 | 2025-07-10 | 레미디 플랜, 인크. | 암 줄기 세포를 표적화하는 암 치료 |
-
2020
- 2020-11-06 AU AU2020378067A patent/AU2020378067A1/en active Pending
- 2020-11-06 EP EP20816347.7A patent/EP4055008A1/en active Pending
- 2020-11-06 CA CA3157315A patent/CA3157315A1/en active Pending
- 2020-11-06 MX MX2022005445A patent/MX2022005445A/es unknown
- 2020-11-06 PH PH1/2022/551081A patent/PH12022551081A1/en unknown
- 2020-11-06 KR KR1020227018395A patent/KR20220110744A/ko active Pending
- 2020-11-06 JP JP2022526226A patent/JP7690470B2/ja active Active
- 2020-11-06 BR BR112022008753A patent/BR112022008753A2/pt unknown
- 2020-11-06 WO PCT/US2020/059329 patent/WO2021092322A1/en not_active Ceased
- 2020-11-06 CN CN202510009927.XA patent/CN119930509A/zh active Pending
- 2020-11-06 CN CN202080091217.1A patent/CN114929672B/zh active Active
-
2022
- 2022-05-03 IL IL292718A patent/IL292718A/en unknown
- 2022-06-03 CO CONC2022/0007910A patent/CO2022007910A2/es unknown
-
2025
- 2025-05-29 JP JP2025089886A patent/JP2025143254A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025143254A (ja) | 2025-10-01 |
| CO2022007910A2 (es) | 2022-08-19 |
| JP7690470B2 (ja) | 2025-06-10 |
| PH12022551081A1 (en) | 2024-06-19 |
| MX2022005445A (es) | 2022-08-10 |
| EP4055008A1 (en) | 2022-09-14 |
| CN114929672B (zh) | 2025-01-21 |
| IL292718A (en) | 2022-07-01 |
| AU2020378067A1 (en) | 2022-05-26 |
| CN119930509A (zh) | 2025-05-06 |
| JP2022553865A (ja) | 2022-12-26 |
| WO2021092322A1 (en) | 2021-05-14 |
| CN114929672A (zh) | 2022-08-19 |
| BR112022008753A2 (pt) | 2022-07-19 |
| US20230023124A1 (en) | 2023-01-26 |
| KR20220110744A (ko) | 2022-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017363307B2 (en) | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof | |
| AU2017363313B2 (en) | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof | |
| JP7643874B2 (ja) | がん幹細胞を標的化するがん治療 | |
| AU2020263390B2 (en) | Degraders of cyclin-dependent kinase 12 (CDK12) and uses thereof | |
| CA3090417A1 (en) | Small molecules for inducing selective protein degradation and uses thereof | |
| CA3157315A1 (en) | Cancer treatments targeting cancer stem cells | |
| EP3876939A1 (en) | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof | |
| JP2022551502A (ja) | 治療、特にｍｙｄ８８変異疾患における使用のためのｈｃｋ阻害剤としてのピラゾロピリミジン誘導体 | |
| CN120659777A (zh) | 募集Cereblon的Bcl-xL/Bcl-2双重降解剂 | |
| CA3217380A1 (en) | Nampt inhibitors and uses thereof | |
| WO2024220676A1 (en) | Mrna degraders and methods of use thereof | |
| WO2019094732A1 (en) | Inhibitors of cyclic-amp response element-binding protein | |
| US12612368B2 (en) | Cancer treatments targeting cancer stem cells | |
| US20250177391A1 (en) | Inhibitors of ddr1 and ddr2 for the treatment of arthritis | |
| HK40120024A (zh) | 靶向癌症干细胞的癌症治疗 | |
| EP3471723A1 (en) | Hedgehog acyltransferase inhibitors and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220912 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241101 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241101 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241101 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250110 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20250512 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251031 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251031 |